EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Serious immune‐related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series

Clément Bresteau iD, Pauline Bonnet, Caroline Robert, Charlotte Mussini, Philippe Saiag, Bruno Buecher, Celeste Lebbe, Matthieu Allez, Robert Benamouzig, Hervé Hagège, Hakim Bécheur, Antoine Meyer iD und 1 weitere

Journal of Gastroenterology and Hepatology · 2023-12 · 38 (12) · 2104-2110

DOI: 10.1111/jgh.16349 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 14.09.2023. Verfasst von Clément Bresteau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France. Hauptthemen laut MEDLINE: Gastrointestinal Diseases, Neoplasms, Enterocolitis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICI) improve the prognosis of many cancers but cause immune‐related adverse events (IrAEs). Limited data are available on upper gastrointestinal (UGI) IrAEs. We describe the clinical characteristics, prognosis, and efficacy of medical therapy in patients with UGI IrAEs.

Methods

This is a retrospective, multicenter cohort study of patients with UGI symptoms and moderate to severe endoscopic UGI lesions, occurring after ICI. Efficacy of induction medical therapy and at the most recent follow‐up was assessed.

Results

Forty patients were included; of these, 34 (85%) received anti‐PD(L)1, either alone ( n = 24) or combined with anti CTLA‐4 ( n = 10). Eighteen patients (45%) had concomitant enterocolitis. All patients had severe endoscopic lesions (erosions, ulcerations, hemorrhage, or necrotic lesions). Three patients who received an inefficient initial medical treatment had a complicated course: One patient died of enterocolitis, one had a pneumomediastinum, and one developed an ulcerated stricture of the pylorus. Thirty‐five patients (88%) were treated with corticosteroids; 28 patients (80%) responded, and 20 (57%) reached clinical remission. Eight patients were treated with infliximab, and six responded (75%). After a median follow‐up of 11 months, 36 patients (90%) were in corticosteroid‐free clinical remission for their UGI symptoms. Endoscopic lesions persisted in 68% of patients.

Conclusions

ICI cause severe UGI IrAEs, which are associated with enterocolitis in approximately half of the patients. Most patients with UGI IrAEs respond to corticosteroids or infliximab. These data support the recommendation to treat these patients without delay and in the same way as those with enterocolitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal DiseasesNeoplasmsEnterocolitisHumansImmune Checkpoint InhibitorsRetrospective StudiesCohort StudiesInfliximabAdrenal Cortex Hormones

Stichwörter der Autor:innen

DuodenitisGastritisImmune checkpoint blockadeImmune-related adverse event

Substanzen

Immune Checkpoint InhibitorsInfliximabAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
  • Université Paris-Saclay, Le Kremlin Bicêtre, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Université Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France.
  • Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Institut Curie, PSL Research University, Départements de Génétique et d'Oncologie Médicale, Paris, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Université Paris Cité, Dermato-Oncology; INSERM U976, Paris, France.

ORCID-Profile: Clément Bresteau, Antoine Meyer, Franck Carbonnel

Zitieren

APA

Bresteau, C., Bonnet, P., Robert, C., Mussini, C., Saiag, P., Buecher, B., Lebbe, C., Allez, M., Benamouzig, R., Hagège, H., Bécheur, H., Meyer, A., & Carbonnel, F. (2023). Serious immune‐related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series. Journal of Gastroenterology and Hepatology, 38(12), 2104-2110. https://doi.org/10.1111/jgh.16349

Vancouver

Bresteau C, Bonnet P, Robert C, Mussini C, Saiag P, Buecher B, et al. Serious immune‐related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series. Journal of Gastroenterology and Hepatology. 2023;38(12):2104-2110. doi:10.1111/jgh.16349

BibTeX
@article{Bresteau2023,
  author = {Bresteau, Clément and Bonnet, Pauline and Robert, Caroline and Mussini, Charlotte and Saiag, Philippe and Buecher, Bruno and Lebbe, Celeste and Allez, Matthieu and Benamouzig, Robert and Hagège, Hervé and Bécheur, Hakim and Meyer, Antoine and Carbonnel, Franck},
  title = {Serious immune‐related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2023},
  volume = {38},
  number = {12},
  pages = {2104--2110},
  doi = {10.1111/jgh.16349}
}
Kostenlos starten →